Search company, investor...

Presidio Pharmaceuticals

presidiopharma.com

Founded Year

2006

Stage

Secondary Market | Alive

Total Raised

$94.08M

About Presidio Pharmaceuticals

Presidio Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics. Presidio's focus is on effective therapies for hepatitis C virus (HCV) infection. With a pipeline consisting of compounds targeting both the NS5A and NS5B proteins of HCV, Presidio is positioned to compete in the growing HCV therapy market. Presidio's goal is to discover and advance small-molecule, antiviral drug candidates that are potent, have pan-genotypic antiviral activity, offer convenient once-daily oral dosing and can be combined with other classes of HCV antivirals to combat viral resistance. The best future combination regimens will require such characteristics, to simplify patient treatment and to ensure that drug therapy will be effective against the wide variety of known HCV genotypes.

Headquarters Location

1700 Owens Street Suite 585

San Francisco, California, 94158,

United States

415-655-7560

Missing: Presidio Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Presidio Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Presidio Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Presidio Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Presidio Pharmaceuticals Patents

Presidio Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/18/2013

4/12/2016

Carbamates, Cyclopropanes, Sulfonamides, Pyrrolidines, Experimental drugs

Grant

Application Date

11/18/2013

Grant Date

4/12/2016

Title

Related Topics

Carbamates, Cyclopropanes, Sulfonamides, Pyrrolidines, Experimental drugs

Status

Grant

Latest Presidio Pharmaceuticals News

Presidio Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 24072018 Prices from USD $250

Oct 1, 2018

08:18 EDT 1 Oct 2018 | BioPortfolio Reports Summary Presidio Pharmaceuticals Inc Presidio Pharmaceuticals is a clinicalstage pharmaceutical company that discovers, develops, and supplies smallmolecule antiviral therapeutics. The company's products include HCV NS5A, protease inhibitor, ravidasvir hydrochloride, NS5B proteins, lead pangenotypic HCV NS5A inhibitor, faldaprevir and nonnucleoside inhibitor. Its lead pangenotypic HCV NS5A inhibitor, ravidasvir hydrochloride has completed phase 1 clinical studies in both healthy volunteers and HCV patients. Presidio Pharmaceuticals' second pangenotypic HCV inhibitor PPI383 is a NS5B nonnucleoside inhibitor currently being evaluated in phase 1 studies. The company also has an extensive intellectual property portfolio for its HCV programs. Presidio Pharmaceuticals is headquartered in San Francisco, California, the US. Presidio Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Presidio Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Presidio Pharmaceuticals founded?

    Presidio Pharmaceuticals was founded in 2006.

  • Where is Presidio Pharmaceuticals's headquarters?

    Presidio Pharmaceuticals's headquarters is located at 1700 Owens Street, San Francisco.

  • What is Presidio Pharmaceuticals's latest funding round?

    Presidio Pharmaceuticals's latest funding round is Secondary Market.

  • How much did Presidio Pharmaceuticals raise?

    Presidio Pharmaceuticals raised a total of $94.08M.

  • Who are the investors of Presidio Pharmaceuticals?

    Investors of Presidio Pharmaceuticals include Sobera Capital, Baker Brothers Investments, Bay City Capital, Panorama Capital, New Leaf Venture Partners and 8 more.

  • Who are Presidio Pharmaceuticals's competitors?

    Competitors of Presidio Pharmaceuticals include Esperance Pharmaceuticals, Rhythm Pharmaceuticals, Questcor Pharmaceuticals, OptiMedica, Conatus Pharmaceuticals and 10 more.

Compare Presidio Pharmaceuticals to Competitors

I
IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

A
Alvine Pharmaceuticals

Alvine Pharmaceuticals is a clinical-stage, specialty biopharmaceutical company focused on the development of biologics targeting autoimmune and inflammatory diseases, including celiac disease. Alvine is focusing clinical development efforts on ALV003, an investigational drug in phase 2 trials that could potentially be the first approved therapeutic treatment for patients with celiac disease. ALV003 is an orally administered mixture of two recombinant gluten-specific proteases, a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP). ALV003 targets gluten and degrades it into small fragments, which, in vitro, diminishes its immunogenicity. ALV003 is being developed as a potential treatment for celiac disease patients in conjunction with a gluten-free diet and is currently in phase 2 clinical development.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Q
Quark Pharmaceuticals

Quark Pharmaceuticals is a development-stage pharmaceutical company discovering and developing RNA interference (RNAi)-based therapeutics.

A
Albea Pharmaceuticals

Through a series of acquisitions, Albea Pharmaceuticals intends to build a rapidly growing, profitable, and pan-European pharmaceutical company with a portfolio of marketed products, a direct sales and marketing organization in the major European countries (UK, Germany, France, Italy and Spain), and a pipeline of products in various stages of clinical development.'

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.